Skip to main content
. 2022 Nov 24;4(4):otac043. doi: 10.1093/crocol/otac043

Table 1.

Prediction of stool biomarkers.

Author Year Study design Patient # Median age (range) Pre-Op diagnosis Pouchitis definition Biomarker Cutoff
(µg/g)
Method; assay Association between biomarker and PDAI Sensitivity (%) Specificity (%)
Yamamoto 2015 Case control 60 34 (21–64) UC PDAI ≥ 7 Fecal calprotectin 56 ELISA; Human Calprotectin Kit 9, (Cell Sciences, Canton, MA, USA) Endoscopy subscore: r = 0.696
p < 0.0001
Total PDAI: r = 0.626
p < 0.0001
100 84
Yamamoto 2015 Case control 60 34 (21–64) UC PDAI ≥ 7 Fecal lactoferrin 50 ELISA; Human Calprotectin Kit 9, (Cell Sciences, Canton, MA, USA)
Endoscopy subscore:
r = 0.676
p < 0.0001
Total PDAI:
r = 0.582
p < 0.0001
90 86
Machiels 2017 Prospective cohort 19 45 (35–51) UC Symptoms + endoscopic inflammation Fecal calprotectin 315.5 QI; Quantum Blue Calprotectin High range Assay, (Buhlmann Laboratories AG Schonenbuch, Switzerland) AUC = 0.833 83.3 72.7
Nishida 2020 Retrospective cohort 49 44 (33–54) UC mPDAI ≥ 5 Neutrophil lymphocyte ratio 2.15 XE-500 hematology analyzer; (Sysmex, Kobe, Japan) AUC = 0.68 72.2 67.7

Abbreviations: AUC: area under the curve, ELISA: enzyme linked immunosorbent assay; PDAI: pouchitis disease activity index; pre-op: pre-operative; QI: quantitative immunochromatography; UC: ulcerative colitis;